Cabometyx

Exelixis, Teva settle Cabometyx patent litigation with 2031 generic license
Fierce Pharma
Mon, 07/24/23 - 11:32 am
Exelixis
Teva Pharmaceutical
patents
legal
Cabometyx
cancer
Roche, Exelixis Suffer Another Late-Stage Cancer Combo Failure
BioSpace
Fri, 03/3/23 - 12:01 pm
Roche
Exelixis
renal cell carcinoma
Tecentriq
Cabometyx
clinical trials
Combo of Roche's Tecentriq and Exelixis' Cabometyx fails another trial, this time in lung cancer
Fierce Pharma
Sun, 12/11/22 - 01:20 pm
Roche
Tecentriq
Exelixis
Cabometyx
clinical trials
non small cell lung cancer
Exelixis drug fails PhIII lung cancer trial with Cabometyx and Tecentriq combo
Endpoints
Fri, 12/9/22 - 10:39 am
Exelixis
Cabometyx
Tecentriq
metastatic non-small cell lung cancer
clinical trials
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Fierce Pharma
Mon, 07/11/22 - 05:48 pm
Exelixis
Cabometyx
kidney cancer
Opdivo
Yervoy
Bristol Myers Squibb
Exelixis throws in the towel on early-stage liver cancer after final readout shows OS flop
Endpoints
Tue, 03/15/22 - 10:39 am
Exelixis
Cabometyx
liver cancer
clinical trials
Exelixis pulls a surprise win in thyroid cancer just days ahead of final Cabometyx readout
Endpoints
Mon, 09/20/21 - 11:57 am
ESMO
Exelixis
thyroid cancer
Cabometyx
ESMO: Exelixis lays out promising early Cabometyx combo data in prostate cancer, but key discrepancies persist
Fierce Pharma
Sat, 09/18/21 - 08:27 pm
ESMO
Exelixis
Cabometyx
Roche
Tecentriq
clinical trials
prostate cancer
In surprising flop, Exelixis' Cabometyx combo with Roche's Tecentriq fails to extend life in liver cancer
Fierce Pharma
Mon, 06/28/21 - 10:50 am
Exelixis
Cabometyx
liver cancer
Bayer
Nexavar
Analysts throw cold water on Exelixis and Roche's prostate cancer data, putting the pair a further step behind Novartis
Endpoints
Tue, 05/25/21 - 11:08 am
Exelixis
Cabometyx
Roche
Tecentriq
prostate cancer
ASCO: Exelixis releases more details on Cabometyx thyroid cancer data that wooed Ipsen
Fierce Pharma
Thu, 05/20/21 - 12:15 pm
ASCO 2021
Ipsen
Exelixis
Cabometyx
thyroid cancer
clinical trials
Exelixis' Cabometyx scores backing from Ipsen in thyroid cancer, with full data release set for ASCO
Fierce Pharma
Wed, 05/12/21 - 11:39 pm
Exelixis
Cabometyx
Ipsen
thyroid cancer
GlaxoSmithKline offloads royalty rights for 2 cancer drugs in $342M windfall it will use to finance consumer spinoff
Endpoints
Thu, 04/1/21 - 11:36 pm
GSK
Cabometyx
Cometriq
Royalty Pharma
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
PM Live
Wed, 02/10/21 - 12:09 am
Bristol Myers Squibb
Exelixix
Opdivo
Cabometyx
kidney cancer
Bristol Myers, Exelixis snag Opdivo-Cabometyx kidney cancer nod to challenge Merck, Pfizer
Fierce Pharma
Mon, 01/25/21 - 11:09 am
Bristol-Myers Squibb
Exelixis
Opdivo
Cabometyx
kidney cancer
FDA
Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC
Motley Fool
Sat, 01/23/21 - 11:35 pm
Exelixis
FDA
Cabometyx
Cometriq
advanced renal cell carcinoma
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Yahoo/Zacks.com
Tue, 08/25/20 - 11:19 am
Exelixis
Cabometyx
FDA
kidney cancer
renal cell carcinoma
Bristol-Myers Squibb
Opdivo
Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer
Pharmaceutical Business Review
Wed, 07/1/20 - 11:03 am
Exelixis
cabozantinib
Cabometyx
Tecentriq
metastatic castration-resistant prostate cancer
clinical trials
Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion
Endpoints
Mon, 04/20/20 - 11:59 pm
Bristol-Myers Squibb
Opdivo
Exelixis
Cabometyx
renal cell carcinoma
kidney cancer
clinical trials
Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study
Motley Fool
Wed, 02/12/20 - 10:27 am
Exelixis
prostate cancer
metastatic castration-resistant prostate cancer
cabozantinib
Cabometyx

Pages